Associate Scientist, Research Laboratory Operations

Benefits

Parental leave

Not verified

Non-birth-parent leave

Not verified

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Not verified checked Jun 7, 2026

Salary

$119K-$149K From the posting source checked Jun 20, 2026

401(k) match

Reported from DOL Form 5500 industry filing (not employer-specific)

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)

$61,842 U.S. median for this role

Projected growth (BLS Employment Projections)

+1.9% - Slower

117% above the BLS role benchmark for operations aggregate.

Matched to SOC 11-1021 - Operations aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Role

Role function

Operations From the posting source checked Jun 20, 2026

Seniority

Mid From the posting source checked Jun 20, 2026

Schedule

Shift type

Not verified

Weekend work

Required From the posting source checked Jun 20, 2026

Company

Company stage

Late From the posting source checked Jun 20, 2026

Equity

Offered Verified - SEC 10-K source checked Jun 20, 2026

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Associate Scientist, Research Laboratory Operations Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is seeking an individual with a strong background in rodent laboratory animal research. The position will receive study designs from scientists and independently execute in vivo pharmacology studies in mice, while demonstrating excellent communication and coordination across teams. In addition, this role will support vivarium management, including management of weekend staff to ensure uninterrupted in vivo operations during weekends and holidays. - Plan, conduct, analyze, and report in vivo studies (efficacy, PK/PD). - Carry out pre-clinical model development and characterization. - Manage and supervise multiple research associates. - Conduct standard vivarium operations-managing inventory/supplies, maintain laboratory equipment, and record keeping. - Contribute to continuous improvement of current SOPS and ensure that the appropriate SOPs are followed by all Vivarium users. - Support adherence to animal welfare guidelines and regulations. - Learn and conduct other in vivo related techniques. - Train junior

Read the full description at www.revmed.com. FewerJobs shows a preview and links to the original posting.